View Item 

Show simple item record

Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association
dc.contributor.authorJohnson, Keith A.
dc.contributor.authorMinoshima, Satoshi
dc.contributor.authorBohnen, Nicolaas I.
dc.contributor.authorDonohoe, Kevin J.
dc.contributor.authorFoster, Norman L.
dc.contributor.authorHerscovitch, Peter
dc.contributor.authorKarlawish, Jason H.
dc.contributor.authorRowe, Christopher C.
dc.contributor.authorCarrillo, Maria C.
dc.contributor.authorHartley, Dean M.
dc.contributor.authorHedrick, Saima
dc.contributor.authorPappas, Virginia
dc.contributor.authorThies, William H.
dc.date.accessioned2020-01-13T15:11:09Z
dc.date.available2020-01-13T15:11:09Z
dc.date.issued2013-01
dc.identifier.citationJohnson, Keith A.; Minoshima, Satoshi; Bohnen, Nicolaas I.; Donohoe, Kevin J.; Foster, Norman L.; Herscovitch, Peter; Karlawish, Jason H.; Rowe, Christopher C.; Carrillo, Maria C.; Hartley, Dean M.; Hedrick, Saima; Pappas, Virginia; Thies, William H. (2013). "Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association." Alzheimer’s & Dementia 9(1): E1-E16.
dc.identifier.issn1552-5260
dc.identifier.issn1552-5279
dc.identifier.urihttps://hdl.handle.net/2027.42/152834
dc.publisherWiley Periodicals, Inc.
dc.subject.otherMCI
dc.subject.otherAlzheimer’s
dc.subject.otherPET
dc.subject.otherFlorbetapir
dc.subject.otherBiomarker
dc.subject.otherBeta‐amyloid
dc.subject.otherDementia
dc.subject.otherRadiopharmaceutical
dc.subject.otherGuidelines
dc.subject.otherAUC
dc.subject.otherImaging
dc.subject.otherAmyloid
dc.titleAppropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152834/1/alzjjalz201301002.pdf
dc.identifier.doi10.1016/j.jalz.2013.01.002
dc.identifier.sourceAlzheimer’s & Dementia
dc.identifier.citedreferenceVL Villemagne, RS Mulligan, S Pejoska, K Ong, G Jones, G O’Keefe, et al. Comparison of 11C‐PiB and 18F‐florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 39: 2012; 983 – 989
dc.identifier.citedreferenceMT Fodero‐Tavoletti, RS Mulligan, N Okamura, S Furumoto, CC Rowe, Y Kudo, et al. In vitro characterisation of BF227 binding to alpha‐synuclein/Lewy bodies. Eur J Pharmacol. 617: 2009; 54 – 58
dc.identifier.citedreferenceG Henriksen, BH Yousefi, A Drzezga, HJ Wester. Development and evaluation of compounds for imaging of beta‐amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging. 35: 2008; S75 – S81
dc.identifier.citedreferenceMA Burack, J Hartlein, HP Flores, L Taylor‐Reinwald, JS Perlmutter, NJ Cairns. In vivo amyloid imaging in autopsy‐confirmed Parkinson disease with dementia. Neurology. 74: 2010; 77 – 84
dc.identifier.citedreferenceA Kadir, A Marutle, G Gonzalez, M Scholl, O Almkvist, M Mousavi, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer’s disease. Brain. 134: 2011; 301 – 317
dc.identifier.citedreferenceK Kantarci, C Yang, JA Schneider, ML Senjem, DA Reyes, VJ Lowe, et al. Ante mortem amyloid imaging and beta‐amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging. 33: 2012; 878 – 885
dc.identifier.citedreferenceMD Ikonomovic, EE Abrahamson, JC Price, RL Hamilton, CA Mathis, WR Paljug, et al. Early AD pathology in a [C‐11]PiB‐negative case: a PiB‐amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 123: 2012; 433 – 447
dc.identifier.citedreferenceR Vandenberghe, K Van Laere, A Ivanoiu, E Salmon, C Bastin, E Triau, et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 68: 2010; 319 – 329
dc.identifier.citedreferenceCC Rowe, U Ackerman, W Browne, R Mulligan, KL Pike, G O’Keefe, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F‐BAY94‐9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7: 2008; 129 – 135
dc.identifier.citedreferenceS Vallabhajosula. Positron emission tomography radiopharmaceuticals for imaging brain beta‐amyloid. Semin Nucl Med. 41: 2011; 283 – 299
dc.identifier.citedreferenceZ Cselenyi, ME Jonhagen, A Forsberg, C Halldin, P Julin, M Schou, et al. Clinical validation of 18F‐AZD4694, an amyloid‐beta‐specific PET radioligand. J Nucl Med. 53: 2012; 415 – 424
dc.identifier.citedreferenceA Jureus, BM Swahn, J Sandell, F Jeppsson, AE Johnson, P Johnstrom, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 114: 2010; 784 – 794
dc.identifier.citedreferenceRowe CC, Pejoska S, Mulligan RS, Gareth Jones G, Chan JG, Svensson S, et al. Head to head comparison of 11C‐PiB and 18F‐AZD4694 (NAV4694) for Aβ imaging in ageing and dementia. J Nucl Med In press.
dc.identifier.citedreferenceJO Rinne, DF Wong, DA Wolk, V Leinonen, SE Arnold, C Buckley, et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol. 124: 2012; 833 – 845
dc.identifier.citedreferenceDA Wolk, Z Zhang, S Boudhar, CM Clark, MJ Pontecorvo, SE Arnold. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound‐B positron emission tomography. J Neurol Neurosurg Psychiatry. 83: 2012; 923 – 926
dc.identifier.citedreferenceSM Landau, C Breault, AD Joshi, M Pontecorvo, CA Mathis, WJ Jagust, et al. Amyloid‐beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 54: 2013; 70 – 77
dc.identifier.citedreferenceNL Foster, JL Heidebrink, CM Clark, WJ Jagust, SE Arnold, NR Barbas, et al. FDG‐PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 130: 2007; 2616 – 2635
dc.identifier.citedreferenceCC Rowe, KA Ellis, M Rimajova, P Bourgeat, KE Pike, G Jones, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 31: 2010; 1275 – 1283
dc.identifier.citedreferenceJC Morris, CM Roe, C Xiong, AM Fagan, AM Goate, DM Holtzman, et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 67: 2010; 122 – 131
dc.identifier.citedreferenceSN Gomperts, DM Rentz, E Moran, JA Becker, JJ Locascio, WE Klunk, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 71: 2008; 903 – 910
dc.identifier.citedreferenceP Edison, CC Rowe, JO Rinne, S Ng, I Ahmed, N Kemppainen, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 79: 2008; 1331 – 1338
dc.identifier.citedreferenceSM Greenberg, T Grabowski, ME Gurol, ME Skehan, RN Nandigam, JA Becker, et al. Detection of isolated cerebrovascular beta‐amyloid with Pittsburgh compound B. Ann Neurol. 64: 2008; 587 – 591
dc.identifier.citedreferenceM Haglund, M Sjobeck, E Englund. Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord. 18: 2004; 132 – 137
dc.identifier.citedreferenceR Natte, ML Maat‐Schieman, J Haan, M Bornebroek, RA Roos, SG van Duinen. Dementia in hereditary cerebral hemorrhage with amyloidosis–Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol. 50: 2001; 765 – 772
dc.identifier.citedreferenceJV Ly, CC Rowe, VL Villemagne, JA Zavala, H Ma, G O’Keefe, et al. Cerebral beta‐amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator‐related hemorrhage. Ann Neurol. 68: 2010; 959 – 962
dc.identifier.citedreferenceGurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez SR, Dumas A, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a PET/MRI study. Ann Neurol In press.
dc.identifier.citedreferenceT Tomiyama, T Nagata, H Shimada, R Teraoka, A Fukushima, H Kanemitsu, et al. A new amyloid beta variant favoring oligomerization in Alzheimer’s‐type dementia. Ann Neurol. 63: 2008; 377 – 387
dc.identifier.citedreferenceGC Roman, DG Wilkinson, RS Doody, SE Black, SP Salloway, RJ Schindler. Donepezil in vascular dementia: combined analysis of two large‐scale clinical trials. Dement Geriatr Cogn Disord. 20: 2005; 338 – 344
dc.identifier.citedreferenceRJ Blendon, JM Benson, EM Wikler, KJ Weldon, J Georges, M Baumgart, et al. The impact of experience with a family member with Alzheimer’s disease on views about the disease across five countries. Int J Alzheimers Dis 2012, In press
dc.identifier.citedreferenceHarvard School of Public Health. International Survey Highlights Great Public Desire to Seek Early Diagnosis of Alzheimer’s. Available at: http://www.hsph.harvard.edu/news/press‐releases/2011‐releases/alzheimers‐international‐survey.html. Accessed: January 11, 2013.
dc.identifier.citedreferenceAlzheimer’s Association. Early Detection. Available at: http://www.alz.org/publichealth/early‐detection.asp. Accessed January 11, 2013.
dc.identifier.citedreferenceChoo IH, Ni R, Scholl M, Wall A, Almkvist O, Nordberg A. Combination of 18F‐FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer’s disease in mild cognitive impairment patients. J Alzheimers Dis. In press.
dc.identifier.citedreferenceA Nordberg, SF Carter, J Rinne, A Drzezga, DJ Brooks, R Vandenberghe, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 40: 2013; 104 – 114
dc.identifier.citedreferenceJP Ioannidis, OA Panagiotou. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta‐analyses. JAMA. 305: 2011; 2200 – 2210
dc.identifier.citedreferenceK Herholz, SF Carter, M Jones. Positron emission tomography imaging in dementia. Br J Radiol. 80: 2007; S160 – S167
dc.identifier.citedreferenceNI Bohnen, S Minoshima. FDG‐PET and molecular brain imaging in the movement disorders clinic. Neurology. 79: 2012; 1306 – 1307
dc.identifier.citedreferenceLM Shaw, H Vanderstichele, M Knapik‐Czajka, CM Clark, PS Aisen, RC Petersen, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 65: 2009; 403 – 413
dc.identifier.citedreferenceAM Fagan, D Head, AR Shah, D Marcus, M Mintun, JC Morris, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 65: 2009; 176 – 183
dc.identifier.citedreferenceJF Burke, RL Albin, RA Koeppe, B Giordani, MR Kilbourn, S Gilman, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain. 134: 2011; 1647 – 1657
dc.identifier.citedreferenceWE Klunk, H Engler, A Nordberg, Y Wang, G Blomqvist, DP Holt, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound‐B. Ann Neurol. 55: 2004; 306 – 319
dc.identifier.citedreferenceKM Langa, NL Foster, EB Larson. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 292: 2004; 2901 – 2908
dc.identifier.citedreferenceMR Patel, JA Spertus, RG Brindis, RC Hendel, PS Douglas, ED Peterson, et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol. 46: 2005; 1606 – 1613
dc.identifier.citedreferenceDG Fryback, JR Thornbury. The efficacy of diagnostic imaging. Med Decision Making. 11: 1991; 88 – 94
dc.identifier.citedreferenceSM Landau, MA Mintun, AD Joshi, RA Koeppe, RC Petersen, PS Aisen, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 72: 2012; 578 – 586
dc.identifier.citedreferenceJohnson KA, Sperling RA, Gidicsin C, Carmasin J, Maye JE, Coleman RE, et al. Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement In press.
dc.identifier.citedreferenceGM McKhann, DS Knopman, H Chertkow, BT Hyman, CR Jack Jr., CH Kawas, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 263 – 269
dc.identifier.citedreferenceB Dubois, HH Feldman, C Jacova, JL Cummings, ST Dekosky, P Barberger‐Gateau, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 9: 2010; 1118 – 1127
dc.identifier.citedreferenceWE Klunk. Amyloid imaging as a biomarker for cerebral beta‐amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 32: 2011; S20 – S36
dc.identifier.citedreferenceVL Villemagne, KE Pike, G Chetelat, KA Ellis, RS Mulligan, P Bourgeat, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 69: 2011; 181 – 192
dc.identifier.citedreferenceR Laforce Jr., GD Rabinovici. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther. 3: 2011; 31
dc.identifier.citedreferenceBJ Bacskai, MP Frosch, SH Freeman, SB Raymond, JC Augustinack, KA Johnson, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 64: 2007; 431 – 434
dc.identifier.citedreferenceMD Ikonomovic, WE Klunk, EE Abrahamson, CA Mathis, JC Price, ND Tsopelas, et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 131: 2008; 1630 – 1645
dc.identifier.citedreferenceNJ Cairns, MD Ikonomovic, T Benzinger, M Storandt, AM Fagan, AR Shah, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 66: 2009; 1557 – 1562
dc.identifier.citedreferenceCM Clark, MJ Pontecorvo, TG Beach, BJ Bedell, RE Coleman, PM Doraiswamy, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid‐beta plaques: a prospective cohort study. Lancet Neurol. 11: 2012; 669 – 678
dc.identifier.citedreferencePM Doraiswamy, RA Sperling, RE Coleman, KA Johnson, EM Reiman, MD Davis, et al. Amyloid‐beta assessed by florbetapir F 18 PET and 18‐month cognitive decline: a multicenter study. Neurology. 79: 2012; 1636 – 1644
dc.identifier.citedreferenceCR Jack Jr., HJ Wiste, P Vemuri, SD Weigand, ML Senjem, G Zeng, et al. Brain beta‐amyloid measures and magnetic resonance imaging atrophy both predict time‐to‐progression from mild cognitive impairment to Alzheimer’s disease. Brain. 133: 2010; 3336 – 3348
dc.identifier.citedreferenceJ Koivunen, T Pirttila, N Kemppainen, S Aalto, SK Herukka, AM Jauhianen, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta‐amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 26: 2008; 378 – 383
dc.identifier.citedreferenceV Leinonen, I Alafuzoff, S Aalto, T Suotunen, S Savolainen, K Nagren, et al. Assessment of beta‐amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11‐labeled Pittsburgh compound B. Arch Neurol. 65: 2008; 1304 – 1309
dc.identifier.citedreferenceV Mok, EY Leung, W Chu, S Chen, A Wong, Y Xiong, et al. Pittsburgh compound B binding in poststroke dementia. J Neurol Sci. 290: 2010; 135 – 137
dc.identifier.citedreferenceA Okello, J Koivunen, P Edison, HA Archer, FE Turkheimer, K Nagren, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C‐PIB PET study. Neurology. 73: 2009; 754 – 760
dc.identifier.citedreferenceGD Rabinovici, HJ Rosen, A Alkalay, J Kornak, AJ Furst, N Agarwal, et al. Amyloid vs FDG‐PET in the differential diagnosis of AD and FTLD. Neurology. 77: 2011; 2034 – 2042
dc.identifier.citedreferenceJ Sojkova, I Driscoll, D Iacono, Y Zhou, KE Codispoti, MA Kraut, et al. In vivo fibrillar beta‐amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 68: 2011; 232 – 240
dc.identifier.citedreferenceDA Wolk, JC Price, JA Saxton, BE Snitz, JA James, OL Lopez, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 65: 2009; 557 – 568
dc.identifier.citedreferenceDA Wolk, ID Grachev, C Buckley, H Kazi, MS Grady, JQ Trojanowski, et al. Association between in vivo fluorine 18‐labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 68: 2011; 1398 – 1403
dc.identifier.citedreferenceN Villain, G Chetelat, B Grassiot, P Bourgeat, G Jones, KA Ellis, et al. Regional dynamics of amyloid‐beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB‐PET longitudinal study. Brain. 135: 2012; 2126 – 2139
dc.identifier.citedreferenceA Forsberg, H Engler, O Almkvist, G Blomquist, G Hagman, A Wall, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 29: 2008; 1456 – 1465
dc.identifier.citedreferenceER Foster, MC Campbell, MA Burack, J Hartlein, HP Flores, NJ Cairns, et al. Amyloid imaging of Lewy body‐associated disorders. Mov Disord. 25: 2010; 2516 – 2523
dc.identifier.citedreferenceV Kepe, B Ghetti, MR Farlow, M Bresjanac, K Miller, SC Huang, et al. PET of brain prion protein amyloid in Gerstmann‐Straussler‐Scheinker disease. Brain Pathol. 20: 2010; 419 – 430
dc.identifier.citedreferenceVL Villemagne, CA McLean, K Reardon, A Boyd, V Lewis, G Klug, et al. 11C‐PiB PET studies in typical sporadic Creutzfeldt‐Jakob disease. J Neurol Neurosurg Psychiatry. 80: 2009; 998 – 1001
dc.identifier.citedreferenceWJ Jagust, D Bandy, K Chen, NL Foster, SM Landau, CA Mathis, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 6: 2010; 221 – 229
dc.identifier.citedreferenceKA Johnson, M Gregas, JA Becker, C Kinnecom, DH Salat, EK Moran, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 62: 2007; 229 – 234
dc.identifier.citedreferenceJC Morris, CM Roe, EA Grant, D Head, M Storandt, AM Goate, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 66: 2009; 1469 – 1475
dc.identifier.citedreferenceTJ Montine, CH Phelps, TG Beach, EH Bigio, NJ Cairns, DW Dickson, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 123: 2012; 1 – 11
dc.identifier.citedreferenceB Dubois, HH Feldman, C Jacova, ST Dekosky, P Barberger‐Gateau, J Cummings, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS‐ADRDA criteria. Lancet Neurol. 6: 2007; 734 – 746
dc.identifier.citedreferenceRC Petersen. Mild cognitive impairment as a diagnostic entity. J Intern Med. 256: 2004; 183 – 194
dc.identifier.citedreferenceRC Petersen. Mild cognitive impairment or questionable dementia?. Arch Neurol. 57: 2000; 643 – 644
dc.identifier.citedreferenceMS Albert, ST DeKosky, D Dickson, B Dubois, HH Feldman, NC Fox, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 270 – 279
dc.identifier.citedreferenceJC Morris. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol. 69: 2012; 700 – 708
dc.identifier.citedreferenceR Ossenkoppele, N Tolboom, JC Foster‐Dingley, SF Adriaanse, R Boellaard, M Yaqub, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 39: 2012; 990 – 1000
dc.identifier.citedreferenceSP Wey, CC Weng, KJ Lin, CH Yao, TC Yen, HF Kung, et al. Validation of an (18)F‐labeled biphenylalkyne as a positron emission tomography imaging agent for beta‐amyloid plaques. Nucl Med Biol. 36: 2009; 411 – 417
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
alzjjalz201301002.pdf
Size:
289.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.